Alexza surges after inhaled antipsychotic drug gets support

Share this article:
Alexza surges after inhaled antipsychotic drug gets support
Alexza surges after inhaled antipsychotic drug gets support

Stock prices for Alexza Pharmaceuticals Inc. recently surged by 25% to 78 cents. This came after the Food and Drug Administration's  Psychopharmacologic Drugs Advisory Committee conditionally backed the drugmaker's plan to sell an inhaled antipsychotic drug. Adusave is approved for people with schizophrenia and bipolar mania. However, the panel's 9-8 vote was contingent on the company using a risk mitigation plan proposed by the FDA.

Share this article:

More in Products

LeadingAge's CAST releases EHR matrix selection tool

LeadingAge's Center for Aging Services Technologies released its 2014 version of a tool to let long-term providers choose the best electronic health record for their facility.

New magnetic badges debut

New magnetic badges debut

Imprint Plus has introduced The Mighty Badge name badge kit, which allows users to create reusable but personalized badges.

Hollister Incorporated celebrates antibacterial foam dressing

Hollister Incorporated celebrates antibacterial foam dressing ...

Hollister Incorporated's new Hydrofera Blue Ready antibacterial foam dressing has been named a "Top 10 Innovation in Podiatry" according to the Podiatry Today journal, as well as a "Top Innovation ...